Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation
- PMID: 18181031
- DOI: 10.1007/s12031-007-9033-7
Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation
Abstract
One of the neuropathological features of Alzheimer's disease (AD) is the deposition of senile plaques containing beta-amyloid (A beta). There is limited evidence for the treatment to arrest A beta pathology of AD. In our present study, we tested the effect of coenzyme Q10 (CoQ10), an endogenous antioxidant and a powerful free radical scavenger, on A beta in the aged transgenic mice overexpressing Alzheimer presenilin 1-L235P (leucine-to-proline mutation at codon 235, 16-17 months old). The treatment by feeding the transgenic mice with CoQ10 for 60 days (1,200 mg kg(-1) day(-1)) partially attenuated A beta overproduction and intracellular A beta deposit in the cortex of the transgenic mice compared with the age-matched untreated transgenic mice. Meanwhile, an increased oxidative stress reaction was detected as evidenced by elevated level of malondialdehyde (MDA) and decreased activity of superoxide dismutase (SOD) in the transgenic mice relative to the wild-type mice, and supplementation of CoQ10 partially decreased MDA level and upregulated the activity of SOD. The results indicate that oxidative stress is enhanced in the brain of the transgenic mice, that this enhancement may further promote A beta 42 overproduction in a vicious formation, and that CoQ10 would be beneficial for the therapy of AD.
Similar articles
-
Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease.J Mol Neurosci. 2010 May;41(1):110-3. doi: 10.1007/s12031-009-9297-1. Epub 2009 Oct 16. J Mol Neurosci. 2010. PMID: 19834824
-
Ubisol-Q10 (a Nanomicellar Water-Soluble Formulation of CoQ10) Treatment Inhibits Alzheimer-Type Behavioral and Pathological Symptoms in a Double Transgenic Mouse (TgAPEswe, PSEN1dE9) Model of Alzheimer's Disease.J Alzheimers Dis. 2018;61(1):221-236. doi: 10.3233/JAD-170275. J Alzheimers Dis. 2018. PMID: 29154270
-
Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease.J Alzheimers Dis. 2011;27(1):211-23. doi: 10.3233/JAD-2011-110209. J Alzheimers Dis. 2011. PMID: 21799249 Free PMC article.
-
Alzheimer's disease and amyloid: culprit or coincidence?Int Rev Neurobiol. 2012;102:277-316. doi: 10.1016/B978-0-12-386986-9.00011-9. Int Rev Neurobiol. 2012. PMID: 22748834 Review.
-
[Alzheimer's disease due to presenilin mutations].Nihon Rinsho. 2004 Jan;62 Suppl:90-4. Nihon Rinsho. 2004. PMID: 15011327 Review. Japanese. No abstract available.
Cited by
-
Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease.J Mol Neurosci. 2010 May;41(1):110-3. doi: 10.1007/s12031-009-9297-1. Epub 2009 Oct 16. J Mol Neurosci. 2010. PMID: 19834824
-
Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives.CNS Drugs. 2019 Oct;33(10):957-969. doi: 10.1007/s40263-019-00658-8. CNS Drugs. 2019. PMID: 31410665 Free PMC article. Review.
-
Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta.Biochim Biophys Acta. 2010 Jan;1802(1):198-204. doi: 10.1016/j.bbadis.2009.07.005. Epub 2009 Jul 16. Biochim Biophys Acta. 2010. PMID: 19616093 Free PMC article. Review.
-
Oxidant/Antioxidant imbalance and the risk of Alzheimer's disease.Curr Alzheimer Res. 2015;12(4):335-49. doi: 10.2174/1567205012666150325182702. Curr Alzheimer Res. 2015. PMID: 25817254 Free PMC article. Review.
-
Coenzyme Q10 Supplementation Increases Removal of the ATXN3 Polyglutamine Repeat, Reducing Cerebellar Degeneration and Improving Motor Dysfunction in Murine Spinocerebellar Ataxia Type 3.Nutrients. 2022 Aug 31;14(17):3593. doi: 10.3390/nu14173593. Nutrients. 2022. PMID: 36079853 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical